NAD+ vs NMN vs NR
Full NAD Precursor Comparison (2026)
NMN vs NR vs IV NAD+ — which NAD precursor is most effective? Compare bioavailability, human trial data, cost, and the best longevity stacking strategies.
Potency Hierarchy
IV NAD+ > NMN ≈ NR > Oral NAD+ (poor bioavailability)
Oral NAD+ supplementation is largely ineffective — NAD+ cannot efficiently cross cell membranes when taken by mouth and is broken down before reaching target tissues. IV NAD+ bypasses this entirely but requires clinical administration. NMN and NR are the practical oral choices.
Who Should Choose Which?
✓You follow the David Sinclair protocol (1g/day oral NMN) and want to align with the most publicly discussed longevity regimen.
✓You have a higher budget and want the most direct NAD+ conversion pathway in oral supplement form.
✓You want the option of sublingual dosing, which some users prefer for faster absorption.
✓You are specifically interested in mitochondrial energy support and cognitive clarity as reported subjective benefits.
✓You want the most published peer-reviewed human RCT data behind your supplement choice — ChromaDex has invested heavily in NR clinical research.
✓Cost is a consideration — NR is generally $40–80/month vs $50–120/month for NMN at comparable doses.
✓You prefer a branded, third-party tested product (Tru Niagen has NSF certification and extensive safety data).
✓You are a Tru Niagen user who is satisfied with the product and wants to optimize rather than switch.
The Missing Piece: NNMT Inhibitors (5-Amino-1MQ)
Most NAD+ discussions focus on adding more precursor — but an equally important lever is reducing NAD+ waste. NNMT (nicotinamide N-methyltransferase) is an enzyme that degrades NAD+ by methylating nicotinamide into MeNAM. High NNMT activity is associated with adiposity, metabolic dysfunction, and accelerated aging.
5-Amino-1MQ is a selective NNMT inhibitor. By blocking this enzyme, it preserves NAD+ that would otherwise be wasted — complementing the supply side (NMN/NR) with a demand-side optimization. The combination of NMN + 5-Amino-1MQ is considered more synergistic than stacking NMN + NR, which share the same conversion bottleneck.
Stacking NMN + NR is not particularly synergistic because they converge on the same intermediate (NMN) before reaching NAD+. You are essentially doubling precursor volume through the same bottleneck. The more effective strategy is: one precursor (NMN or NR) + one waste-reduction agent (NNMT inhibitor).
Making an Informed Choice Between Nad and Nmn
Choosing between Nad and Nmn depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.
Head-to-head clinical trial data between Nad and Nmn is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.
Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.
NAD+ vs Nmn: Common Questions
NMN vs NR vs IV NAD+ — which NAD precursor is most effective? Compare bioavailability, human trial data, cost, and the best longevity stacking strategies.
Yes. Shotlee supports tracking NAD+ Vs Nmn doses, side effects, and health metrics. It is free.
Neither is universally better — the right choice depends on your individual health profile, treatment goals, side effect tolerance, insurance coverage, and prescriber recommendation. Clinical trial data shows efficacy differences in specific populations, but personal response varies. Track your experience with either medication in Shotlee to generate objective comparison data with your healthcare provider.
Switching between these medications should be done under medical supervision. Your prescriber will consider factors including your current response, reason for switching, dose equivalence, and transition timing. Use Shotlee to document your outcomes on the current medication so you have a clear baseline for comparison after switching.
The decision should be made collaboratively with your healthcare provider based on your specific health profile, treatment goals, insurance coverage, side effect tolerance, and practical considerations like administration route and frequency. Use the comparison data in this guide as a starting framework for discussion, not as a definitive recommendation. Track your outcomes on whichever option you choose in Shotlee so you have objective data to evaluate if a switch becomes appropriate later.
Switching between medications should always be done under medical supervision. Your provider will consider factors including your response to the current treatment, the reason for switching, appropriate dose equivalence or titration schedules, and the expected transition timeline. Having detailed tracking data from your current protocol in Shotlee provides the objective baseline your provider needs to plan and evaluate a medication transition effectively.
References
- [1]ReviewRajman L et al. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metab. 2018;27(3):529-547.
- [2]Clinical TrialYoshino J et al. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011;14(4):528-536.
Track Your NAD+ Vs Nmn Protocol in Shotlee
Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.
🚀 Use Shotlee for Free